Macrocycle Therapeutics to Treat Life-threatening Diseases

Authors

  • Gokhan Batur Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil
  • Philipp Ermert Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil
  • Johann Zimmermann Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil
  • Daniel Obrecht Polyphor Ltd, Hegenheimermattweg 125, CH-4123 Allschwil;, Email: daniel.obrecht@polyphor.com

DOI:

https://doi.org/10.2533/chimia.2021.508

PMID:

34233814

Keywords:

Antibiotic, Breast cancer, Cxcr4 inhibitor, Macrocycle, Protein epitope mimetic

Abstract

Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.
CHIMIA Vol. 75 No. 06(2021): Peptide Chemistry in Switzerland

Downloads

Published

2021-06-30

Issue

Vol. 75 No. 6 (2021): Peptide Chemistry in Switzerland

Section

Scientific Articles

License

Copyright (c) 2021 Gokhan Batur, Philipp Ermert, Johann Zimmermann, Daniel Obrecht

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
G. Batur, P. Ermert, J. Zimmermann, D. Obrecht, Chimia 2021, 75, 508, DOI: 10.2533/chimia.2021.508.